Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.

UNLABELLED The present study was a proof-of-concept study to provide an initial indication of the efficacy and safety of imaging malignant breast tumors using (99m)Tc-NC100692. The agent is a small peptide with high affinity for integrin receptors that are upregulated and expressed preferentially on proliferating endothelial cells. METHODS Sixteen patients with suggestive mammographic findings and 4 patients with benign lesions were included. The "standard of truth" was based on the histopathologic diagnosis of the recruited patients. All subjects received up to 75 microg of (99m)Tc-NC100692 with an average (99m)Tc activity of 694 MBq (range, 561-747 MBq). Safety endpoints were treatment-emergent adverse events (AEs) and changes in a limited physical examination, electrocardiogram (ECG) recordings, blood biochemistry, hematology, coagulation, vital signs, and urine analysis after administration of (99m)Tc-NC100692 and throughout the 24-h follow-up. Static images and SPECT were acquired between 40 min and 2.5 h after injection of the agent. Two experienced nuclear medicine physicians read the images in a nonblinded fashion. RESULTS Nineteen of 22 malignant lesions were detected using (99m)Tc-NC100692 scintigraphy. Twenty lesions confirmed as malignant by histopathology were seen on mammography or ultrasound. Two additional lesions were identified from histopathology alone. Safety parameters evaluated through the follow-up period of 2.5 h included clinical laboratory tests, vital signs, and ECG. Five of 20 subjects experienced nonserious AEs, and all AEs were classified as mild. One subject experienced an AE (dysgeusia) possibly related to administration of (99m)Tc-NC100692. This AE was mild and lasted only for a few minutes. No deaths, serious AEs, or withdrawals due to AEs occurred during the study. CONCLUSION Nineteen of 22 malignant lesions (86%) were clearly detected via scintigraphic imaging after administration of (99m)Tc-NC100692. Overall, the efficacy data in subjects with suspected breast lesions suggest that (99m)Tc-NC100692 scintigraphy may be effective in detecting malignant lesions. The use of (99m)Tc-NC100692 in subjects with breast cancer is safe and well tolerated. Further studies are warranted to assess the clinical potential of (99m)Tc-NC100692.

[1]  P. Aspelin,et al.  99mTc-sestamibi uptake and histological malignancy grade in invasive breast carcinoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Milind Rajopadhye,et al.  Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. , 2002, Cancer research.

[3]  Richard T. Lee,et al.  Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. , 2006, American journal of physiology. Heart and circulatory physiology.

[4]  H. Ghandehari,et al.  Targeting tumor angiogenic vasculature using polymer-RGD conjugates. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[5]  David A. Cheresh,et al.  Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.

[6]  G. Loudos,et al.  Comparative evaluation of linear and cyclic 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. , 2006, Anticancer research.

[7]  I. Mena,et al.  Prone scintimammography in patients with suspicion of carcinoma of the breast. , 1994, Journal of the American College of Surgeons.

[8]  G. Lip,et al.  Angiogenesis: basic pathophysiology and implications for disease. , 2003, European heart journal.

[9]  S. Schnitt,et al.  Diagnostic accuracy of 99mTc-sestamibi breast imaging: multicenter trial results. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Albert J. Sinusas,et al.  Noninvasive Imaging of Angiogenesis With a 99mTc-Labeled Peptide Targeted at &agr;v&bgr;3 Integrin After Murine Hindlimb Ischemia , 2005 .

[11]  J. Folkman,et al.  Angiogenesis and apoptosis. , 2003, Seminars in cancer biology.

[12]  Tim Davidson,et al.  Can scintimammography with 99mTc-MIBI identify multifocal and multicentric primary breast cancer? , 2001 .

[13]  J. Sampalis,et al.  Breast Cancer Diagnosis by Scintimammography: A Meta-analysis and Review of the Literature , 2003, Breast Cancer Research and Treatment.

[14]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[15]  M A Horton,et al.  The alpha v beta 3 integrin "vitronectin receptor". , 1997, The international journal of biochemistry & cell biology.

[16]  Horst Kessler,et al.  Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.

[17]  H. Ghandehari,et al.  Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[19]  J. Buscombe,et al.  Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  M Schwaiger,et al.  Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.